› 7uem

X-ray diffraction
2.31Å resolution

Genomic and structural basis for the human anti-alpha-galactosyl antibody response

Released:
DOI: 10.2210/pdb7uem/pdb
PDB entry 7uem coloured by chain, front view.
PDB entry 7uem coloured by chain, side view.
PDB entry 7uem coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Genetic and structural basis of the human anti-α-galactosyl antibody response.
Langley DB, Schofield P, Nevoltris D, Jackson J, Jackson KJL, Peters TJ, Burk M, Matthews JM, Basten A, Goodnow CC, van Nunen S, Reed JH, Christ D
OpenAccess logo Proc Natl Acad Sci U S A 119 e2123212119 (2022)
PMID: 35867757

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-226480 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (3 distinct):
Light chain Fab of antibody HKB7 Chains: C, L
Molecule details ›
Chains: C, L
Length: 219 amino acids
Theoretical weight: 24 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
Heavy chain Fab arm of antibody HKB7 Chains: D, H
Molecule details ›
Chains: D, H
Length: 229 amino acids
Theoretical weight: 24.47 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens

Ligands and Environments

Carbohydrate polymer : NEW Components: GAL, GLA
Ligand GAL 2 x GAL
Ligand GLA 2 x GLA
1 bound ligand:
Ligand CL 15 x CL
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: AUSTRALIAN SYNCHROTRON BEAMLINE MX2
Spacegroup: C2
Unit cell:
a: 86.937Å b: 65.931Å c: 151.513Å
α: 90° β: 90.91° γ: 90°
R-values:
R R work R free
0.191 0.189 0.231
Expression system: Homo sapiens

Quick links

Citations

2 review citations

Antibody production and tolerance to the α-gal epitope as models for understanding and preventing the immune response to incompatible ABO carbohydrate antigens and for α-gal therapies.
Galili U. (2023)
1 more